RE: CC interview24 Jan 2026 15:54
CC mentioned use AI in drug design, so...
Q: Are Computer-Aided Drug Discovery and Computer-Aided Molecular Design the same thing, and are they the latest techniques?
Computer-Aided Drug Design/Discovery (CADD) and Computer-Aided Molecular Design (CAMD) are not strictly the same, although they are heavily overlapping fields used interchangeably in many contexts. CADD is the broader umbrella term for using computational techniques to discover and develop new drugs. CAMD is often considered a specialized subset or a closely related approach focused on designing specific molecule structures from scratch or optimizing them based on desired physiochemical properties, sometimes extending beyond pharmaceuticals into materials science.
• CADD: Focuses on the process of identifying, optimizing, and developing potential drugs using techniques like molecular docking, QSAR (Quantitative Structure-Activity Relationship), and virtual screening.
• CAMD: Focuses on the design and engineering of the molecule's structure itself, often involving de novo design (designing from scratch) to create molecules with specific, desired properties.
While the concepts of CADD/CAMD have been in use since the 1980s and 1990s, they are not stagnant. They have evolved into "modern CADD/CAMD," which currently represents the leading edge in pharmaceutical research. The latest, state-of-the-art developments in this field, particularly for 2024–2025, include:
• AI and Machine Learning Integration: The integration of deep learning (DL), Generative Adversarial Networks (GANs), and Reinforcement Learning (RL) has fundamentally shifted the field from "computer-aided" to "computer-driven" discovery, allowing for the generation of entirely new molecular structures.
• Protein Structure Prediction (AlphaFold2): Tools like AlphaFold2, RoseTTAFold, and ESMFold have revolutionized the field by enabling rapid, accurate 3D protein structure prediction, which is crucial for structure-based drug design (SBDD).
• Gigascale Virtual Screening: The ability to screen, on-demand, virtual compound libraries consisting of billions of compounds (e.g., Enamine REAL database) using high-performance computing (HPC) and GPU acceleration.
• Quantum Computing: While still early, quantum computing is being explored to revolutionize molecular simulations and handle vast molecular spaces.
• Multimodal AI Models: Moving beyond simple models, new AI approaches integrate both ligand and target information to make more accurate predictions about binding affinities and toxicity (ADMET properties).
CADD - The entire drug discovery pipeline - Target ID, Lead Optimization, Virtual Screening
CAMD - The structure of the molecule - De novo Design, Molecular Modeling
Latest - AI/ML, Generative Models, AlphaFold2 - High-speed screening, Predicting new drugs
In essence, CADD/CAMD are not "new" as concepts, but their modern, AI-driven iterations are the absolute state-of-t
Sign In
Follow the stocks
